Where is eMed headquartered?

eMed is headquartered in Miami, USA. The company has a team of 500+ people.

eMed operates in the AI in Healthcare sector. A digital healthcare platform pioneering the 'Test-to-Treat' model by combining at-home diagnostic testing with live-proctored verification and immediate AI-driven telehealth services. Democratizes access to clinical-grade healthcare by enabling users to test, receive verified results, and obtain prescriptions from home in minutes, significantly reducing the time-to-treatment for acute and chronic conditions.

When was eMed founded?

eMed was founded in 2020. It is based in Miami, USA.

Who is the CEO of eMed?

Linda Yaccarino is the CEO of eMed. The company was founded in 2020.

Where is eMed located?

eMed is headquartered in Miami, USA.

What funding stage is eMed at?

eMed is currently at the Growth stage (Valued at $2B+ following a $200M funding round and the strategic acquisition of Babylon Health's UK assets). stage.

How many employees does eMed have?

eMed has approximately 500+ employees.

eMed

Category: AI in Healthcare

A digital healthcare platform pioneering the 'Test-to-Treat' model by combining at-home diagnostic testing with live-proctored verification and immediate AI-driven telehealth services. eMed was founded in 2020. The company is led by Linda Yaccarino. Based in Miami, USA. Team size: 500+. Total funding raised: $200.0M. Latest round: Series A ($200.0M, Mar 2024). Key investors include Aon Consulting, Tom Brady, Linda Yaccarino, Jeff Aronin (Paragon Biosciences), Ara Cohen (Knighthead Capital), Antonio Gracias (Valor Equity Partners), Joe Lonsdale (8VC), R.J. Melman (Lettuce Entertain You), Tom Ricketts (Chicago Cubs).

Founded: 2020
Headquarters: Miami, USA
Team size: 500+
Total funding: $200.0M

Value proposition

Democratizes access to clinical-grade healthcare by enabling users to test, receive verified results, and obtain prescriptions from home in minutes, significantly reducing the time-to-treatment for acute and chronic conditions.

Products and solutions

Digital 'Test-to-Treat' Platform (Acute care for COVID-19, Flu, Strep, UTI), AI-Powered Weight Management Program (GLP-1 clinical support and monitoring), Live-Proctored At-Home Diagnostic Kits, eMed UK / GP at Hand (Digital-first primary care services), Chronic Care Management Dashboard

Unique value

Pioneered the first virtually proctored at-home testing platform that meets regulatory standards for clinical validity, bridging the gap between home convenience and laboratory-grade reliability.

Target customer

Individual consumers, large employers, health insurance providers, and government health systems (e.g., UK NHS).

Industries served

Telehealth, HealthTech & Digital Health, Diagnostics, Pharmaceuticals, Public Health

Technology advantage

Integrates proprietary real-time proctoring software with Babylon Health’s legacy AI triage and digital-first primary care infrastructure to create a full-stack healthcare delivery engine.

How they differentiate

Proprietary live-proctoring technology that ensures clinical validity for at-home diagnostics, enabling a seamless 'Test-to-Treat' model with immediate telehealth intervention.

Main competitors

LetsGetChecked, Ro, Everlywell

Key partnerships

Abbott (Partnership for BinaxNOW rapid tests), National Health Service (NHS) UK, Aon (Strategic investment and distribution), Quest Diagnostics (Laboratory integration)

Notable customers

National Health Service (NHS) UK, Abbott, Aon

Major milestones

Pioneered the first virtually proctored at-home COVID-19 test in 2020, Acquired Babylon Health's UK assets (including GP at Hand) in September 2023, Launched AI-driven weight management and chronic care programs in 2024, Linda Yaccarino appointed CEO in August 2025, Secured $200M Series A funding at a $2B+ valuation in March 2026, Launched empathic agentic AI platform and capitated employer care model in 2026

Growth metrics

Achieved a valuation of over $2 billion following $200M Series A in March 2026; 500+ employees; 90%+ member adherence rate on GLP-1 program; average 21 lbs weight loss; 99% of participants see biomarker improvement within 6 months.

Market positioning

Full-stack digital health platform bridging the gap between at-home diagnostic testing and immediate clinical care/pharmacy services.

Geographic focus

United States, United Kingdom

Patents and IP

Holds proprietary IP related to remote proctoring technology and digital verification of rapid diagnostic tests (specific patent filings are generally held under eMed Digital Health).

About Linda Yaccarino

Linda Yaccarino previously served as CEO of X Corp (Twitter) from 2023-2025 and as Chairman of Global Advertising and Partnerships at NBCUniversal from 2011-2023. She is a media and advertising executive with extensive experience in digital platforms and partnerships.

More AI in Healthcare companies

Official website: https://www.emed.com